Group Sequential Methods. for Clinical Trials. Christopher Jennison, Dept of Mathematical Sciences, University of Bath, UK
|
|
- Arthur Harrison
- 6 years ago
- Views:
Transcription
1 Group Sequential Methods for Clinical Trials Christopher Jennison, Dept of Mathematical Sciences, University of Bath, UK PSI, London, 22 October
2 Plan of talk 1. Why sequential monitoring? , Dodge & Romig: 2stage sampling s: methods for manufacturing s and 0s: methods for medical studies s: group sequential tests. Types of test, including equivalence, and types of stopping rule 7. Sequential theory, including survival data 8. A unified approach for group sequential design, monitoring and analysis 9. Nuisance parameters: updating a design 10. Survival data example 11. Error spending 2
3 1. Motivation of interim monitoring In clinical trials, animal trials and epidemiological studies there are reasons of ethics administration (accrual,compliance,...) economics to monitor progress and accumulating data. Subjects should not be exposed to unsafe, ineffective or inferior treatments. National and international guidelines call for interim analyses to be performed and reported. It is now standard practice for medical studies to have a Data and Safety Monitoring Board to oversee the study and consider the option of early termination. 3
4 The need for special methods There is a danger that multiple looks at data can lead to overinterpretation of interim results Overall Type I error rate applying repeated significance tests at ff = 5% to accumulating data Number of tests Error rate Pocock (1983) Clinical Trials Table 10.1, Armitage, et al. (199), Table 2. 4
5 2. Acceptance sampling Dodge & Romig (1929), Bell Systems Technical Journal. Components are classified as effective or defective. A batch is only accepted if the proportion of defectives in a sample is sufficiently low. Number defective Reject Reject Continue Accept Accept n 1 n 1 + n 2 Number of items sampled 5
6 3. Manufacturing production Barnard and Wald developed methods for industrial production and development. Wald (1947) published his Sequential Probability Ratio Test (SPRT) for testing between two simple hypotheses. Stopping boundaries and continuation region Sample sum S n Φ ψψψψψψψψψψψψψψψψψψψψψψψψψψψψψψψψψψψ Φ ψψψψψψψψψψψψψψψψψψψψψψψψψψψψψψψψψψψ X n
7 The SPRT Ostensibly, the SPRT tests between H 1 : = 1 and H 2 : = 2. low high ff ff 1 2 In reality, it is usually used to choose between two sets of values. The SPRT has an optimality property if only 1 and 2 need be considered. However, it assumes continuous monitoring of the data and has no upper bound on the possible sample size. 7
8 4. Sequential monitoring of clinical trials In the 1950s, Armitage and Bross took sequential testing from industrial applications to comparative clinical trials. Their plans were fully sequential but with a bounded maximum sample size. The restricted test, Armitage (1957), S n Reject H 0 (((((((((((((((((((((((((((((( Accept H 0 n hhhhhhhhhhhhhhhhhhhhhhhhhhhhhh Reject H 0 testing H 0 : = 0 against = 0, where is the treatment difference. 8
9 Armitage s repeated significance test Armitage, McPherson & Rowe (199) applied a significance test of H 0 : = 0 after each new pair of observations. Numerical calculations gave the nominal significance level ff 0 to use in each of N repeated significance tests for an overall type I error probability ff. S n, ΦΦ A A@! οοοοοψψψψψψψ(((((((((( Reject H 0! Accept H 0 n l Reject H 0 QHHaaPPPPXXXXX```````hhhhhhhhhh 9
10 5. Group sequential tests In practice, one can only analyse a clinical trial on a small number of occasions. Shaw (19): talked of a block sequential analysis. Elfring & Schultz (1973): gave group sequential designs to compare two binary responses. McPherson (1974): use of repeated significance tests at a small number of analyses. Pocock (1977): provided clear guidelines for group sequential tests with given type I error and power. O Brien & Fleming (1979): an alternative to Pocock s repeated significance tests. 10
11 Pocock s repeated significance test To test H 0 : = 0 against = 0. Use standardised test statistics Z k, k = 1;:::;K. Stop to reject H 0 at analysis k if jz k j > c: If H 0 has not been rejected by analysis K, stop and accept H 0. Z k Reject H 0 Accept H 0 k Reject H 0 11
12 . Types of hypothesis testing problems Twosided test: testing H 0 : = 0 against = 0. Onesided test: testing H 0 :» 0 against > 0. Equivalence tests: onesided to show treatment A is as good as treatment B, within a margin ffi. twosided to show two treatment formulations are equal within an accepted tolerance. 12
13 A twosided equivalence test Conduct a test of H 0 : = 0 vs = 0 with type I error rate ff and power 1 fi at = ±ffi. Declare equivalence if H 0 is accepted. PrfDeclare equivalenceg 1 ff fi ffi 0 ffi Here, fi represents the consumer s risk. In design and implementation, give priority to attaining power 1 fi at = ±ffi. 13
14 Types of early stopping 1. Stopping to reject H 0 : no treatment difference Allows progress from a positive outcome Avoids exposing further patients to the inferior treatment Appropriate if no further checks are needed on, say, treatment safety or longterm effects. 2. Stopping to accept H 0 : no treatment difference Stopping for futility or abandoning a lost cause Saves time and effort when a study is unlikely to lead to a positive conclusion. 14
15 Onesided tests If we are only interested in showing that a new treatment is superior to a control, we should test H 0 :» 0 against > 0, requiring PrfReject H 0 j = 0g = ff, PrfReject H 0 j = ffig = 1 fi. A typical boundary is: Z k H P P P ρ ρρ Reject H 0 ```!!!! " "" Accept H 0 k E.g., Whitehead (1997), Pampallona & Tsiatis (1994). 15
16 Twosided tests with early stopping for H 0 Early stopping in favour of H 0 may be included in a twosided test to abandon a lost cause. Z k H H a aa Reject H 0 XXX hhh P PP Accept H 0 k Q QQ Φ Φ!!! οοο ((( Reject H 0 1
17 Onesided tests of H 0 : = 0 vs > 0 Early stopping to Z k Reject H 0 reject H 0 or accept H 0 I k Accept H 0 Early stopping only Z k Reject H 0 to reject H 0 I k Accept H 0 Abandoning a lost Z k Reject H 0 cause: Early stopping only I k to accept H 0 Accept H 0 17
18 Twosided tests of H 0 : = 0 vs = 0 Early stopping to reject H 0 Z k Reject H 0 Accept H 0 I k Reject H 0 An inner wedge: Early stopping to reject H 0 or Z k Reject H 0 Accept H 0 I k accept H 0 Reject H 0 Z k Reject H 0 Abandoning a lost cause: Only an inner wedge Accept H 0 I k Reject H 0 18
19 7. Joint distribution of parameter estimates Reference: Jennison & Turnbull, Ch. 11 Suppose our main interest is in the parameter and let b k be the estimate of based on data at analysis k. The information for at analysis k is I k = fvar( b k )g 1 ; k = 1;:::;K: Canonical joint distribution of b 1 ;:::; b K In very many situations, b 1 ;:::; b K are approximately multivariate normal, b k ο N( ; fi k g 1 ); k = 1;:::;K; and Cov( b k1 ; b k2 ) = Var( b k2 ) = fi k2 g 1 for k 1 < k 2 : 19
20 Sequential distribution theory The preceding results for the joint distribution of b 1 ;:::; b K can be demonstrated directly for: a single normal mean, = μ A μ B ; the effect size in a comparison of two normal means. The results also apply when is a parameter in: a general normal linear, a general model fitted by maximum likelihood (large sample theory). So, we have the theory to support general comparisons, including adjustment for covariates if required. 20
21 Canonical joint distribution of zstatistics In testing H 0 : = 0,thestandardised statistic at analysis k is Z k = b k q Var( b k ) = b k p Ik : For this, (Z 1 ;:::;Z K ) is multivariate normal, Z k ο N( p I k ; 1); k = 1;:::;K, Cov(Z k1 ;Z k2 )= q I k1 =I k2 for k 1 < k 2. 21
22 Canonical joint distribution of score statistics The score statistics S k = Z k p Ik, are also multivariate normal with S k ο N( I k ; I k ); k = 1;:::;K: The score statistics possess the independent increments property, Cov(S k S k 1 ; S k 0 S k 0 1 ) = 0 for k = k0 : It can be helpful to know the score statistics behave as Brownian motion with drift observed at times I 1 ;:::;I K. 22
23 Survival data The canonical joint distributions also arise for a) the estimates of a parameter in Cox s proportional hazards regression model b) a sequence of logrank statistics (score statistics) for comparing two survival curves and to zstatistics formed from these. For survival data, observed information is roughly proportional to the number of failures seen. Special types of group sequential test are needed to handle unpredictable and unevenly spaced information levels: see error spending tests. 23
24 8. Group sequential design, monitoring and analysis To have the usual features of a fixed sample study, Randomisation, stratification, etc., Adjustment for baseline covariates, Appropriate testing formulation, Inference on termination, plus the opportunity for early stopping. Response distributions: Normal, unknown variance Binomial Cox model or logrank test for survival data Normal linear models Generalized linear models 24
25 General approach Think through a fixed sample version of the study. Decide on the type of early stopping, number of analyses, and choice of stopping boundary: these will imply increasing the fixed sample size by a certain inflation factor. In interim monitoring, compute the standardised statistic Z k at each analysis and compare with critical values (calculated specifically in the case of an error spending test). On termination, one can obtain Pvalues and confidence intervals possessing the usual frequentist interpretations. 25
26 Example of a two treatment comparison, normal response, 2sided test Cholesterol reduction trial Treatment A: new, experimental treatment Treatment B: current treatment Primary endpoint: reduction in serum cholesterol level over a four week period Aim: To test for a treatment difference. High power should be attained if the mean cholesterol reduction differs between treatments by 0.4 mmol/l. DESIGN MONITORING ANALYSIS 2
27 DESIGN How would we design a fixedsample study? Denote responses by X Ai, i = 1;:::;n A, on treatment A, X Bi, i = 1;:::;n B, on treatment B. Suppose each X Ai ο N(μ A ;ff 2 ) and X Bi ο N(μ B ;ff 2 ): Problem: to test H 0 : μ A = μ B with twosided type I error probability ff = 0:05 and power 0.9 at jμ A μ B j = ffi = 0:4. We suppose ff 2 is known to be 0.5. (Facey, Controlled Clinical Trials, 1992) 27
28 Fixed sample design Standardised test statistic Z = μx A μ XB qff 2 =n A + ff 2 =n B : Under H 0, Z ο N(0; 1) so reject H 0 if jzj > Φ 1 (1 ff=2): Let μ A μ B =. Ifn A = n B = n, Z ο N( q 2ff 2 =n ; 1) so, to attain desired power at = ffi, aimfor n = fφ 1 (1 ff=2) + Φ 1 (1 fi)g 2 2ff 2 =ffi 2 = (1:90 + 1:282) 2 (2 0:5)=0:4 2 = 5:7; i.e., subjects on each treatment. 28
29 Group sequential design Specify type of early termination: stop early to reject H 0 Number of analyses: 5(fewerifwestopearly) Stopping boundary: O Brien & Fleming. Reject H 0 at analysis k, k = 1;:::;5, if jz k j > c p f5=kg, Z k k where Z k is the standardised statistic based on data at analysis k. 29
30 Example: cholesterol reduction trial O Brien & Fleming design From tables (JT, Table 2.3) or computer software c = 2:040 for ff = 0:05 so reject H 0 at analysis k if jz k j > 2:040 q 5=k: Also, for specified power, inflate the fixed sample size by a factor (JT, Table 2.4) IF = 1:02 to get the maximum sample size 1:02 5:7 = 8: Divide this into 5 groups of 13 or 14 observations per treatment. 30
31 Some designs with K analyses O Brien & Fleming Reject H 0 at analysis k if jz k j > c q K=k: Z k k Pocock Reject H 0 at analysis k if Z k jz k j > c: k Wang & Tsiatis, shape Reject H 0 at analysis k if Z k jz k j > c (k=k) 1=2 : k ( = 0 gives O Brien & Fleming, = 0:5 gives Pocock ) 31
32 Example: cholesterol reduction trial Properties of different designs Sample sizes are per treatment. Fixed sample size is. K Maximum Expected sample size sample size = 0 = 0:2 = 0:4 O Brien & Fleming Wang & Tsiatis, = 0:25 Pocock
33 MONITORING Implementing the OBF test Divide the total sample size of 8 per treatment into 5 groups of roughly equal size, e.g., 14 in groups 1 to 3, 13 in groups 4 and 5. At analysis k, define μx (k) A = 1 n Ak nx Ak X Ai ; i=1 μ X (k) B = 1 n Bk nx Bk X Bi i=1 and Z k = q μx (k) A μ X (k) B ff 2 (1=n Ak + 1=n Bk ) : Stop to reject H 0 if jz k j > 2:040 q 5=k; k = 1;:::;5: Accept H 0 if jz 5 j < 2:
34 Implementing the 5analysis OBF test The stopping rule gives type I error rate ff = 0:050 and power at = 0:4 if group sizes are equal to their design values. Note the minor effects of discrete group sizes. Perturbations in error rates also arise from small variations in the actual group sizes. For major departures from planned group sizes, we should really follow the error spending approach see later. 34
35 ANALYSIS Analysis on termination The sample space consists of all possible pairs (k; Z k ) on termination: Z k k 35
36 Analysis on termination First, order the sample space. Z k ) ρ ρ ρ ρ ρ ρ ρ= Ψ Ψ k P PPPP Pq Z ZZ Z We define Pvalues and confidence intervals with respect to this ordering. 3
37 The Pvalue for H 0 : μ A = μ B is the probability under H 0 of observing such an extreme outcome. Z k ) ρ ρ ρ ρ ρ Λ ρ ρ= Ψ Λ Λ Ψ k P PPPP ZZ @R E.g., if the test stops at analysis 3 with Z 3 = 4:2, the twosided Pvalue is Pr =0 fjz 1 j 4:5 or jz 2 j 3:23 or jz 3 j 4:2g = 0:0013: 37
38 A confidence interval on termination Suppose the test terminates at analysis k Λ with Z k Λ = Z Λ. A 100(1 ff)% confidence interval for = μ A μ B is the interval ( 1 ; 2 ) where Pr = 1 fan outcome above (k Λ ;Z Λ )g= ff=2 and Pr = 2 fan outcome below (k Λ ;Z Λ )g= ff=2: E.g., if the test stops at analysis 3 with Z 3 = 4:2, the 95% confidence interval for is (0:24; 0:91); using our specified ordering. Compare: fixed sample CI would be (0:35; 0:95). 38
39 9. Updating a design as a nuisance parameter is estimated The case of unknown variance We can design as for the case of known variance but use an estimate of ff 2 initially. If in doubt, err towards overestimating ff 2 in order to safeguard the desired power. At analysis k, estimate ff 2 by P s 2 k = (XAi X μ(k) A )2 + P (X Bi X μ(k) B )2 n Ak + n Bk 2 In place of Z k, define tstatistics T k = μx (k) A X μ(k) B qs 2 k (1=n Ak + 1=n Bk ) ; : then test at the same significance level used for Z k when ff 2 is known. 39
40 Updating the target sample size Recall, maximum sample size is set to be the fixed sample size multiplied by the Inflation Factor. In a 5group O Brien & Fleming design for the cholesterol example this is 1:02 fφ 1 (1 ff=2) + Φ 1 (1 fi)g 2 2ff 2 =ffi 2 = 134:8 ff 2 : After choosing the first group sizes using an initial estimate of ff 2, at each analysis k = 1; 2;::: we can reestimate the target for n A5 and n B5 as 134:8 s 2 k and modify future group sizes to achieve this. 40
41 Example: updating the sample size Initially: With initial estimate ^ff 2 = 0:5, aim for n A5 = n B5 = 134:8 0:5 = 8. Plan 14 observations per treatment group. Analysis 1: With n A1 = n B1 = 14 and s 2 1 = 0:80, aim for n A5 = n B5 = 134:8 0:80 = 108. For now, keep to 14 obs. per treatment group. Analysis 2: With n A2 = n B2 = 28 and s 2 2 = 0:9, aim for n A5 = n B5 = 134:8 0:9 = 93. Now increase group size to 22 obs. per treatment. 41
42 Example: updating the sample size Analysis 3: With n A3 = n B3 = 50 and s 2 3 = 0:5, aim for n A5 = n B5 = 134:8 0:5 = 88. Set next group size to 19 obs. per treatment. Analysis 4: With n A4 = n B4 = 9 and s 2 4 = 0:72, aim for n A5 = n B5 = 134:8 0:72 = 97. Set final group size to 28 obs. per treatment. Analysis 5: With n A5 = n B5 = 97, suppose s 2 5 = 0:74, so the target is n A5 = n B5 = 134:8 0:74 = 100 and the test may be slightly underpowered. 42
43 Remarks on reestimating sample size The target information for = μ A μ B is I max = IF fφ 1 (1 ff=2) + Φ 1 (1 fi)g 2 =ffi 2 = 1:02 (1:90 + 1:282) 2 =0:4 2 = 7:4: The relation between information and sample size I k = ρ 1 n Ak + 1 n Bk ff 2ff 1 involves the unknown ff 2. Hence, the initial uncertainty about the necessary sample size. In effect, we proceed by monitoring observed information: I max = 7:4 I 1 I 2 I 3 I 4 I 5 Information NB, state I max = 7:4 in the protocol, not n = ::: 43
44 Recapitulation Designing a group sequential test: Formulate the testing problem Create a fixed sample study design Choose number of analyses and boundary shape parameter Set maximum sample size equal to fixed sample size times the inflation factor Monitoring: Find observed information at each analysis Compare zstatistics with critical values Analysis: Pvalue and confidence interval on termination This method can be applied to many response distributions and statistical models. 44
45 10. A survival data example Oropharynx Clinical Trial Data (Kalbfleisch & Prentice, 1980, Appendix 1, Data Set II) Patient survival was compared on experimental Treatment A and standard Treatment B. Number Number entered of deaths k Date Trt A Trt B Trt A Trt B 1 12/ / / / /
46 The logrank statistic At stage k, observed number of deaths is d k. Elapsed times between study entry and failure are fi 1;k < fi 2;k < ::: < fi dk ;k (assuming no ties). Define r ia;k and r ib;k numbers at risk on Treatments A and B at fi i;k r ik = r ia;k + r ib;k total number at risk at fi i;k O k E k = P d k i=1 V k = P d k i=1 r ib;k r ik r ia;k r ib;k r 2 ik observed number of deaths on Treatment B at stage k expected number of deaths on Treatment B at stage k. variance of O k The standardised logrank statistic at stage k is Z k = O k E p k : Vk 4
47 Proportional hazards model Assume hazard rates h A on Treatment A and h B on Treatment B are related by h B (t) = h A (t): The log hazard ratio is = ln( ). Then, approximately, and Z k ο N( p I k ; 1) Cov(Z k1 ;Z k2 )= p (I k1 =I k2 ); 1» k 1» k 2» K; where I k = V k. For ß 1, wehavei k ß V k ß d k =4. 47
48 Design of the Oropharynx trial Onesided test of H 0 :» 0 vs > 0. Under the alternative > 1, i.e., Treatment A is better. Require: type I error probability ff = 0:05, power 1 fi = 0:95 at = 0:, i.e., = 1:8. Information needed for a fixed sample study is I f = fφ 1 (ff) + Φ 1 (fi)g 2 0: 2 = 30:0 Under the approximation I ß d=4 the total number of failures to be observed is d f = 4 I f = 120:2. 48
49 Design of the Oropharynx trial For a onesided test with up to 5 analyses, we could use a standard design created for equally spaced information levels. Z k H P P P ρ ρρ Reject H 0 ```!!!! " "" Accept H 0 I k However, increments in information between analyses will be unequal and unpredictable. This leads to consideration of an error spending design. 49
50 11. Error spending tests Lan & DeMets (1983) presented twosided tests which spend type I error as a function of observed information. Maximum information design: Error spending function f(i) f(i) ff Φ!! ρ " # ρ#!!φ" I max I k Set the boundary at analysis k to give cumulative Type I error f(i k ). Accept H 0 if I max is reached without rejecting H 0. 50
51 Error spending tests Analysis 1: Observed information I 1. Z k Reject H 0 if jz 1 j > c 1 where I 1 k Pr =0 fjz 1 j > c 1 g = f(i 1 ): Analysis 2: Cumulative information I 2. Reject H 0 if jz 2 j > c 2 where Pr =0 fjz 1 j < c 1 ; jz 2 j > c 2 g Z k I 1 I 2 k = f(i 2 ) f(i 1 ): etc. 51
52 Onesided error spending tests For a onesided test, define f(i) and g(i) to specify how type I and type II error probabilities are spent as a function of observed information. f(i) ff ρ "Φ!! ρ g(i) fi ρ "Φ!! ρ!! Φ"!! Φ" I max I I max I At analysis k, set boundary values (a k ; b k ) so that Pr =0 freject H 0 by analysis kg = f(i k ); Pr =ffi faccept H 0 by analysis kg = g(i k ): Power family of error spending tests: f(i) and g(i) / (I=I max ) ρ. 52
53 Onesided error spending tests 1. Values fa k ;b k g are easily computed using iterative formulae of McPherson, Armitage & Rowe (199). 2. Computation of (a k ; b k ) does not depend on future information levels, I k+1 ; I k+2 ; :::. 3. In a maximum information design, the study continues until the boundary is crossed or an analysis is reached with I k I max. 4. The value of I max should be chosen so that boundaries converge at the final analysis under a typical sequence of information levels, e.g., I k = (k=k) I max ; k = 1;:::;K: 53
54 Overrunning If one reaches I K > I max, solving for a K and b K is liable to give a K > b K. Z k H P P P ρ ρρ ``` " "" Reject H 0 ffi a K bk... " "" " "" k Accept H 0 Keeping b K as calculated guarantees type I error probability of exactly ff. So, reduce a K to b K and gain extra power. Overrunning may also occur if I K = I max but the information levels deviate from the equally spaced values (say) used in choosing I max. 54
55 Underrunning If a final information level I K < I max is imposed, solving for a K and b K is liable to give a K < b K. Z k H P P P ρ ρρ ``` " "" Reject H 0 b K ((( ffi ak!! k... Accept H 0 Again, with b K as calculated, the type I error probability is exactly ff. This time, increase a K to b K and attained power will be a little below 1 fi. 55
56 A onesided error spending design for the Oropharynx trial Specification: onesided test of H 0 :» 0 vs > 0, type I error probability ff = 0:05, power 1 fi = 0:95 at = ln( ) = 0:. At the design stage, assume K = 5 equally spaced information levels. Use a powerfamily test with ρ = 2, i.e., error spent is proportional to (I=I max ) 2. Information of a fixed sample test is inflated by a factor R(K; ff; fi; ρ) = 1:101 (JT, Table 7.). So, we require I max = 1:101 30:0 = 33:10, which needs a total of 4 33:10 = 132:4 deaths. 5
57 Summary data and critical values for the Oropharynx trial We construct error spending boundaries for the information levels actually observed. This gives boundary values (a 1 ; b 1 );:::;(a 5 ; b 5 ) for the standardised statistics Z 1 ;:::;Z 5. Number Number k entered of deaths I k a k b k Z k This stopping rule would have led to termination at the 2nd analysis. 57
58 Covariate adjustment in the Oropharynx trial Covariate information was recorded for subjects: gender, initial condition, Tstaging, Nstaging. These can be included in a proportional hazards regression model along with treatment effect fi 1. The goal is then to test H 0 : fi 1 = 0 against the onesided alternative fi 1 > 0. At stage k we have the estimate ^fi(k) 1, v k = d Var(^fi(k) 1 ), I k = v 1 k and Z k = ^fi(k) 1 =p v k. All these are available from standard Cox regression software. The standardised statistics Z 1 ;:::;Z 5 have, approximately, the canonical joint distribution. 58
59 Covariateadjusted group sequential analysis of the Oropharynx trial Constructing the error spending test gives boundary values (a 1 ; b 1 );:::;(a 5 ; b 5 )for Z 1 ;:::;Z 5. k I k a k b k ^fi(k) 1 Z k Under this model and stopping rule, the study would have terminated at the 3rd analysis. 59
60 Further topics Chapters of Jennison & Turnbull, Group Sequential Methods with Applications to Clinical Trials: Ch 9. Ch 10. Ch 12. Ch 15. Ch 1. Ch 17. Ch 18. Ch 19. Repeated confidence intervals Stochastic curtailment Special methods for binary data Multiple endpoints Multiarmed trials Adaptive treatment assignment Bayesian approaches Numerical computations for group sequential tests 0
Interim Monitoring of. Clinical Trials. Christopher Jennison, Dept of Mathematical Sciences, University of Bath, UK
Interim Monitoring of Clinical Trials Christopher Jennison, Dept of Mathematical Sciences, University of Bath, UK http://www.bath.ac.uk/οmascj Magdeburg, 1 October 2003 1 Plan of talk 1. Why sequential
More informationGroup Sequential Methods. for Clinical Trials. Christopher Jennison, Dept of Mathematical Sciences, University of Bath, UK
Group Sequential Methods for Clinical Trials Christopher Jennison, Dept of Mathematical Sciences, University of Bath, UK http://wwwbathacuk/ mascj University of Malaysia, Kuala Lumpur March 2004 1 Plan
More informationGroup Sequential Tests for Delayed Responses. Christopher Jennison. Lisa Hampson. Workshop on Special Topics on Sequential Methodology
Group Sequential Tests for Delayed Responses Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj Lisa Hampson Department of Mathematics and Statistics,
More informationMonitoring clinical trial outcomes with delayed response: incorporating pipeline data in group sequential designs. Christopher Jennison
Monitoring clinical trial outcomes with delayed response: incorporating pipeline data in group sequential designs Christopher Jennison Department of Mathematical Sciences, University of Bath http://people.bath.ac.uk/mascj
More informationGroup Sequential Designs: Theory, Computation and Optimisation
Group Sequential Designs: Theory, Computation and Optimisation Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj 8th International Conference
More informationInterim Monitoring of Clinical Trials: Decision Theory, Dynamic Programming. and Optimal Stopping
Interim Monitoring of Clinical Trials: Decision Theory, Dynamic Programming and Optimal Stopping Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj
More informationOptimising Group Sequential Designs. Decision Theory, Dynamic Programming. and Optimal Stopping
: Decision Theory, Dynamic Programming and Optimal Stopping Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj InSPiRe Conference on Methodology
More informationThe Design of Group Sequential Clinical Trials that Test Multiple Endpoints
The Design of Group Sequential Clinical Trials that Test Multiple Endpoints Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj Bruce Turnbull
More informationIndependent Increments in Group Sequential Tests: A Review
Independent Increments in Group Sequential Tests: A Review KyungMann Kim kmkim@biostat.wisc.edu University of Wisconsin-Madison, Madison, WI, USA July 13, 2013 Outline Early Sequential Analysis Independent
More informationSample size re-estimation in clinical trials. Dealing with those unknowns. Chris Jennison. University of Kyoto, January 2018
Sample Size Re-estimation in Clinical Trials: Dealing with those unknowns Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj University of Kyoto,
More informationGroup Sequential Tests for Delayed Responses
Group Sequential Tests for Delayed Responses Lisa Hampson Department of Mathematics and Statistics, Lancaster University, UK Chris Jennison Department of Mathematical Sciences, University of Bath, UK Read
More informationMonitoring clinical trial outcomes with delayed response: Incorporating pipeline data in group sequential and adaptive designs. Christopher Jennison
Monitoring clinical trial outcomes with delayed response: Incorporating pipeline data in group sequential and adaptive designs Christopher Jennison Department of Mathematical Sciences, University of Bath,
More informationThe SEQDESIGN Procedure
SAS/STAT 9.2 User s Guide, Second Edition The SEQDESIGN Procedure (Book Excerpt) This document is an individual chapter from the SAS/STAT 9.2 User s Guide, Second Edition. The correct bibliographic citation
More informationThe Design of a Survival Study
The Design of a Survival Study The design of survival studies are usually based on the logrank test, and sometimes assumes the exponential distribution. As in standard designs, the power depends on The
More informationComparing Adaptive Designs and the. Classical Group Sequential Approach. to Clinical Trial Design
Comparing Adaptive Designs and the Classical Group Sequential Approach to Clinical Trial Design Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj
More informationTesting a secondary endpoint after a group sequential test. Chris Jennison. 9th Annual Adaptive Designs in Clinical Trials
Testing a secondary endpoint after a group sequential test Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj 9th Annual Adaptive Designs in
More informationAn Adaptive Futility Monitoring Method with Time-Varying Conditional Power Boundary
An Adaptive Futility Monitoring Method with Time-Varying Conditional Power Boundary Ying Zhang and William R. Clarke Department of Biostatistics, University of Iowa 200 Hawkins Dr. C-22 GH, Iowa City,
More informationSAS/STAT 15.1 User s Guide The SEQDESIGN Procedure
SAS/STAT 15.1 User s Guide The SEQDESIGN Procedure This document is an individual chapter from SAS/STAT 15.1 User s Guide. The correct bibliographic citation for this manual is as follows: SAS Institute
More informationOptimal group sequential designs for simultaneous testing of superiority and non-inferiority
Optimal group sequential designs for simultaneous testing of superiority and non-inferiority Fredrik Öhrn AstraZeneca R & D Mölndal, SE-431 83 Mölndal, Sweden and Christopher Jennison Department of Mathematical
More informationSAMPLE SIZE RE-ESTIMATION FOR ADAPTIVE SEQUENTIAL DESIGN IN CLINICAL TRIALS
Journal of Biopharmaceutical Statistics, 18: 1184 1196, 2008 Copyright Taylor & Francis Group, LLC ISSN: 1054-3406 print/1520-5711 online DOI: 10.1080/10543400802369053 SAMPLE SIZE RE-ESTIMATION FOR ADAPTIVE
More informationAdaptive Designs: Why, How and When?
Adaptive Designs: Why, How and When? Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj ISBS Conference Shanghai, July 2008 1 Adaptive designs:
More informationPubh 8482: Sequential Analysis
Pubh 8482: Sequential Analysis Joseph S. Koopmeiners Division of Biostatistics University of Minnesota Week 8 P-values When reporting results, we usually report p-values in place of reporting whether or
More informationCHL 5225H Advanced Statistical Methods for Clinical Trials: Multiplicity
CHL 5225H Advanced Statistical Methods for Clinical Trials: Multiplicity Prof. Kevin E. Thorpe Dept. of Public Health Sciences University of Toronto Objectives 1. Be able to distinguish among the various
More informationPubh 8482: Sequential Analysis
Pubh 8482: Sequential Analysis Joseph S. Koopmeiners Division of Biostatistics University of Minnesota Week 5 Course Summary So far, we have discussed Group sequential procedures for two-sided tests Group
More informationBiometrika Trust. Biometrika Trust is collaborating with JSTOR to digitize, preserve and extend access to Biometrika.
Biometrika Trust Discrete Sequential Boundaries for Clinical Trials Author(s): K. K. Gordon Lan and David L. DeMets Reviewed work(s): Source: Biometrika, Vol. 70, No. 3 (Dec., 1983), pp. 659-663 Published
More informationPublished online: 10 Apr 2012.
This article was downloaded by: Columbia University] On: 23 March 215, At: 12:7 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 172954 Registered office: Mortimer
More informationPubh 8482: Sequential Analysis
Pubh 8482: Sequential Analysis Joseph S. Koopmeiners Division of Biostatistics University of Minnesota Week 12 Review So far... We have discussed the role of phase III clinical trials in drug development
More informationStatistics and Probability Letters. Using randomization tests to preserve type I error with response adaptive and covariate adaptive randomization
Statistics and Probability Letters ( ) Contents lists available at ScienceDirect Statistics and Probability Letters journal homepage: wwwelseviercom/locate/stapro Using randomization tests to preserve
More informationMultiple Testing in Group Sequential Clinical Trials
Multiple Testing in Group Sequential Clinical Trials Tian Zhao Supervisor: Michael Baron Department of Mathematical Sciences University of Texas at Dallas txz122@utdallas.edu 7/2/213 1 Sequential statistics
More informationGroup-Sequential Tests for One Proportion in a Fleming Design
Chapter 126 Group-Sequential Tests for One Proportion in a Fleming Design Introduction This procedure computes power and sample size for the single-arm group-sequential (multiple-stage) designs of Fleming
More informationInverse Sampling for McNemar s Test
International Journal of Statistics and Probability; Vol. 6, No. 1; January 27 ISSN 1927-7032 E-ISSN 1927-7040 Published by Canadian Center of Science and Education Inverse Sampling for McNemar s Test
More informationPower assessment in group sequential design with multiple biomarker subgroups for multiplicity problem
Power assessment in group sequential design with multiple biomarker subgroups for multiplicity problem Lei Yang, Ph.D. Statistical Scientist, Roche (China) Holding Ltd. Aug 30 th 2018, Shanghai Jiao Tong
More informationRepeated confidence intervals for adaptive group sequential trials
STATISTICS IN MEDICINE Statist. Med. 2007; 26:5422 5433 Published online 4 October 2007 in Wiley InterScience (www.interscience.wiley.com).3062 Repeated confidence intervals for adaptive group sequential
More informationOverrunning in Clinical Trials: a Methodological Review
Overrunning in Clinical Trials: a Methodological Review Dario Gregori Unit of Biostatistics, Epidemiology and Public Health Department of Cardiac, Thoracic and Vascular Sciences dario.gregori@unipd.it
More informationMETHODS OF EVALUATION OF PERFORMANCE OF ADAPTIVE DESIGNS ON TREATMENT EFFECT INTERVALS AND METHODS OF
METHODS OF EVALUATION OF PERFORMANCE OF ADAPTIVE DESIGNS ON TREATMENT EFFECT INTERVALS AND METHODS OF DESIGNING TWO-STAGE WINNER DESIGNS WITH SURVIVAL OUTCOMES BY FANG FANG A dissertation submitted to
More informationLecture 7 Time-dependent Covariates in Cox Regression
Lecture 7 Time-dependent Covariates in Cox Regression So far, we ve been considering the following Cox PH model: λ(t Z) = λ 0 (t) exp(β Z) = λ 0 (t) exp( β j Z j ) where β j is the parameter for the the
More informationFrequency table: Var2 (Spreadsheet1) Count Cumulative Percent Cumulative From To. Percent <x<=
A frequency distribution is a kind of probability distribution. It gives the frequency or relative frequency at which given values have been observed among the data collected. For example, for age, Frequency
More informationStatistical Aspects of Futility Analyses. Kevin J Carroll. nd 2013
Statistical Aspects of Futility Analyses Kevin J Carroll March Spring 222013 nd 2013 1 Contents Introduction The Problem in Statistical Terms Defining Futility Three Common Futility Rules The Maths An
More informationPubh 8482: Sequential Analysis
Pubh 8482: Sequential Analysis Joseph S. Koopmeiners Division of Biostatistics University of Minnesota Week 7 Course Summary To this point, we have discussed group sequential testing focusing on Maintaining
More informationAdaptive Treatment Selection with Survival Endpoints
Adaptive Treatment Selection with Survival Endpoints Gernot Wassmer Institut für Medizinische Statisti, Informati und Epidemiologie Universität zu Köln Joint wor with Marus Roters, Omnicare Clinical Research,
More informationDivision of Pharmacoepidemiology And Pharmacoeconomics Technical Report Series
Division of Pharmacoepidemiology And Pharmacoeconomics Technical Report Series Year: 2013 #006 The Expected Value of Information in Prospective Drug Safety Monitoring Jessica M. Franklin a, Amanda R. Patrick
More informationGroup sequential designs with negative binomial data
Group sequential designs with negative binomial data Ekkehard Glimm 1 Tobias Mütze 2,3 1 Statistical Methodology, Novartis, Basel, Switzerland 2 Department of Medical Statistics, University Medical Center
More informationGroup sequential designs for Clinical Trials with multiple treatment arms
Group sequential designs for Clinical Trials with multiple treatment arms Susanne Urach, Martin Posch Cologne, June 26, 2015 This project has received funding from the European Union s Seventh Framework
More informationPubh 8482: Sequential Analysis
Pubh 8482: Sequential Analysis Joseph S. Koopmeiners Division of Biostatistics University of Minnesota Week 10 Class Summary Last time... We began our discussion of adaptive clinical trials Specifically,
More information4. Issues in Trial Monitoring
4. Issues in Trial Monitoring 4.1 Elements of Trial Monitoring Monitoring trial process and quality Infrastructure requirements and DSMBs 4.2 Interim analyses: group sequential trial design 4.3 Group sequential
More informationStat Seminar 10/26/06. General position results on uniqueness of nonrandomized Group-sequential decision procedures in Clinical Trials Eric Slud, UMCP
Stat Seminar 10/26/06 General position results on uniqueness of nonrandomized Group-sequential decision procedures in Clinical Trials Eric Slud, UMCP OUTLINE I. Two-Sample Clinical Trial Statistics A.
More informationA Gatekeeping Test on a Primary and a Secondary Endpoint in a Group Sequential Design with Multiple Interim Looks
A Gatekeeping Test in a Group Sequential Design 1 A Gatekeeping Test on a Primary and a Secondary Endpoint in a Group Sequential Design with Multiple Interim Looks Ajit C. Tamhane Department of Industrial
More informationReports of the Institute of Biostatistics
Reports of the Institute of Biostatistics No 02 / 2008 Leibniz University of Hannover Natural Sciences Faculty Title: Properties of confidence intervals for the comparison of small binomial proportions
More informationA simulation study for comparing testing statistics in response-adaptive randomization
RESEARCH ARTICLE Open Access A simulation study for comparing testing statistics in response-adaptive randomization Xuemin Gu 1, J Jack Lee 2* Abstract Background: Response-adaptive randomizations are
More informationCalculation of Efficacy and Futiltiy Boundaries using GrpSeqBnds (Version 2.3)
Calculation of Efficacy and Futiltiy Boundaries using GrpSeqBnds (Version 2.3) Grant Izmirlian March 26, 2018 1 Introduction The function GrpSeqBnds computes efficacy and futility boundaries given the
More informationFULL LIKELIHOOD INFERENCES IN THE COX MODEL
October 20, 2007 FULL LIKELIHOOD INFERENCES IN THE COX MODEL BY JIAN-JIAN REN 1 AND MAI ZHOU 2 University of Central Florida and University of Kentucky Abstract We use the empirical likelihood approach
More informationNon-Inferiority Tests for the Ratio of Two Proportions in a Cluster- Randomized Design
Chapter 236 Non-Inferiority Tests for the Ratio of Two Proportions in a Cluster- Randomized Design Introduction This module provides power analysis and sample size calculation for non-inferiority tests
More informationAdaptive Extensions of a Two-Stage Group Sequential Procedure for Testing a Primary and a Secondary Endpoint (II): Sample Size Re-estimation
Research Article Received XXXX (www.interscience.wiley.com) DOI: 10.100/sim.0000 Adaptive Extensions of a Two-Stage Group Sequential Procedure for Testing a Primary and a Secondary Endpoint (II): Sample
More informationPubH 7470: STATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH
PubH 7470: STATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH The First Step: SAMPLE SIZE DETERMINATION THE ULTIMATE GOAL The most important, ultimate step of any of clinical research is to do draw inferences;
More informationA Type of Sample Size Planning for Mean Comparison in Clinical Trials
Journal of Data Science 13(2015), 115-126 A Type of Sample Size Planning for Mean Comparison in Clinical Trials Junfeng Liu 1 and Dipak K. Dey 2 1 GCE Solutions, Inc. 2 Department of Statistics, University
More informationGood Confidence Intervals for Categorical Data Analyses. Alan Agresti
Good Confidence Intervals for Categorical Data Analyses Alan Agresti Department of Statistics, University of Florida visiting Statistics Department, Harvard University LSHTM, July 22, 2011 p. 1/36 Outline
More informationINTERIM MONITORING AND CONDITIONAL POWER IN CLINICAL TRIALS. by Yanjie Ren BS, Southeast University, Nanjing, China, 2013
INTERIM MONITORING AND CONDITIONAL POWER IN CLINICAL TRIALS by Yanjie Ren BS, Southeast University, Nanjing, China, 2013 Submitted to the Graduate Faculty of the Graduate School of Public Health in partial
More informationExact Inference for Adaptive Group Sequential Designs
STATSTCS N MEDCNE Statist. Med. 2013; 00:1 [Version: 2002/09/18 v1.11] Exact nference for Adaptive Group Sequential Designs Ping Gao 1, Lingyun Liu 2, Cyrus R. Mehta 2,3 1 The Medicines Company, 2 Cytel
More informationc Copyright 2014 Navneet R. Hakhu
c Copyright 04 Navneet R. Hakhu Unconditional Exact Tests for Binomial Proportions in the Group Sequential Setting Navneet R. Hakhu A thesis submitted in partial fulfillment of the requirements for the
More informationTwo-Phase, Three-Stage Adaptive Designs in Clinical Trials
Japanese Journal of Biometrics Vol. 35, No. 2, 69 93 (2014) Preliminary Report Two-Phase, Three-Stage Adaptive Designs in Clinical Trials Hiroyuki Uesaka 1, Toshihiko Morikawa 2 and Akiko Kada 3 1 The
More informationTMA 4275 Lifetime Analysis June 2004 Solution
TMA 4275 Lifetime Analysis June 2004 Solution Problem 1 a) Observation of the outcome is censored, if the time of the outcome is not known exactly and only the last time when it was observed being intact,
More informationBios 6649: Clinical Trials - Statistical Design and Monitoring
Bios 6649: Clinical Trials - Statistical Design and Monitoring Spring Semester 2015 John M. Kittelson Department of Biostatistics & Informatics Colorado School of Public Health University of Colorado Denver
More informationSample size determination for a binary response in a superiority clinical trial using a hybrid classical and Bayesian procedure
Ciarleglio and Arendt Trials (2017) 18:83 DOI 10.1186/s13063-017-1791-0 METHODOLOGY Open Access Sample size determination for a binary response in a superiority clinical trial using a hybrid classical
More informationBIOS 312: Precision of Statistical Inference
and Power/Sample Size and Standard Errors BIOS 312: of Statistical Inference Chris Slaughter Department of Biostatistics, Vanderbilt University School of Medicine January 3, 2013 Outline Overview and Power/Sample
More informationBiost 518 Applied Biostatistics II. Purpose of Statistics. First Stage of Scientific Investigation. Further Stages of Scientific Investigation
Biost 58 Applied Biostatistics II Scott S. Emerson, M.D., Ph.D. Professor of Biostatistics University of Washington Lecture 5: Review Purpose of Statistics Statistics is about science (Science in the broadest
More informationSurvival Analysis for Case-Cohort Studies
Survival Analysis for ase-ohort Studies Petr Klášterecký Dept. of Probability and Mathematical Statistics, Faculty of Mathematics and Physics, harles University, Prague, zech Republic e-mail: petr.klasterecky@matfyz.cz
More informationSample Size Determination
Sample Size Determination 018 The number of subjects in a clinical study should always be large enough to provide a reliable answer to the question(s addressed. The sample size is usually determined by
More informationGroup sequential designs for negative binomial outcomes
Group sequential designs for negative binomial outcomes Tobias Mütze a, Ekkehard Glimm b,c, Heinz Schmidli b, and Tim Friede a,d a Department of Medical Statistics, University Medical Center Göttingen,
More informationLecture 12. Multivariate Survival Data Statistics Survival Analysis. Presented March 8, 2016
Statistics 255 - Survival Analysis Presented March 8, 2016 Dan Gillen Department of Statistics University of California, Irvine 12.1 Examples Clustered or correlated survival times Disease onset in family
More informationclinical trials Abstract Multi-arm multi-stage (MAMS) trials can improve the efficiency of the drug
A multi-stage drop-the-losers design for multi-arm clinical trials James Wason 1, Nigel Stallard 2, Jack Bowden 1, and Christopher Jennison 3 1 MRC Biostatistics Unit, Cambridge 2 Warwick Medical School,
More informationGeneralized Likelihood Ratio Statistics and Uncertainty Adjustments in Efficient Adaptive Design of Clinical Trials
Sequential Analysis, 27: 254 276, 2008 Copyright Taylor & Francis Group, LLC ISSN: 0747-4946 print/1532-4176 online DOI: 10.1080/07474940802241009 Generalized Likelihood Ratio Statistics and Uncertainty
More informationGroup Sequential Trial with a Biomarker Subpopulation
Group Sequential Trial with a Biomarker Subpopulation Ting-Yu (Jeff) Chen, Jing Zhao, Linda Sun and Keaven Anderson ASA Biopharm Workshop, Sep 13th. 2018 1 Outline Motivation: Phase III PD-L1/PD-1 Monotherapy
More informationMultivariate Survival Analysis
Multivariate Survival Analysis Previously we have assumed that either (X i, δ i ) or (X i, δ i, Z i ), i = 1,..., n, are i.i.d.. This may not always be the case. Multivariate survival data can arise in
More informationAN INVESTIGATION OF TWO-STAGE TESTS. Marc Vandemeulebroecke. Otto-von-Guericke-Universität Magdeburg. and. Schering AG
AN INVESTIGATION OF TWO-STAGE TESTS Marc Vandemeulebroecke Otto-von-Guericke-Universität Magdeburg and Schering AG Abstract: Two-stage tests may be defined in terms of a combination function for the p-values
More information4. Comparison of Two (K) Samples
4. Comparison of Two (K) Samples K=2 Problem: compare the survival distributions between two groups. E: comparing treatments on patients with a particular disease. Z: Treatment indicator, i.e. Z = 1 for
More informationOn Using Truncated Sequential Probability Ratio Test Boundaries for Monte Carlo Implementation of Hypothesis Tests
On Using Truncated Sequential Probability Ratio Test Boundaries for Monte Carlo Implementation of Hypothesis Tests (to appear in Journal of Computational and Graphical Statistics) Michael P. Fay National
More informationPASS Sample Size Software. Poisson Regression
Chapter 870 Introduction Poisson regression is used when the dependent variable is a count. Following the results of Signorini (99), this procedure calculates power and sample size for testing the hypothesis
More informationImproving Efficiency of Inferences in Randomized Clinical Trials Using Auxiliary Covariates
Improving Efficiency of Inferences in Randomized Clinical Trials Using Auxiliary Covariates Anastasios (Butch) Tsiatis Department of Statistics North Carolina State University http://www.stat.ncsu.edu/
More informationStatistics in medicine
Statistics in medicine Lecture 4: and multivariable regression Fatma Shebl, MD, MS, MPH, PhD Assistant Professor Chronic Disease Epidemiology Department Yale School of Public Health Fatma.shebl@yale.edu
More informationWelcome! Webinar Biostatistics: sample size & power. Thursday, April 26, 12:30 1:30 pm (NDT)
. Welcome! Webinar Biostatistics: sample size & power Thursday, April 26, 12:30 1:30 pm (NDT) Get started now: Please check if your speakers are working and mute your audio. Please use the chat box to
More informationSurvival Regression Models
Survival Regression Models David M. Rocke May 18, 2017 David M. Rocke Survival Regression Models May 18, 2017 1 / 32 Background on the Proportional Hazards Model The exponential distribution has constant
More informationTwo-stage Adaptive Randomization for Delayed Response in Clinical Trials
Two-stage Adaptive Randomization for Delayed Response in Clinical Trials Guosheng Yin Department of Statistics and Actuarial Science The University of Hong Kong Joint work with J. Xu PSI and RSS Journal
More informationPower and Sample Size Calculations with the Additive Hazards Model
Journal of Data Science 10(2012), 143-155 Power and Sample Size Calculations with the Additive Hazards Model Ling Chen, Chengjie Xiong, J. Philip Miller and Feng Gao Washington University School of Medicine
More informationSample Size and Power I: Binary Outcomes. James Ware, PhD Harvard School of Public Health Boston, MA
Sample Size and Power I: Binary Outcomes James Ware, PhD Harvard School of Public Health Boston, MA Sample Size and Power Principles: Sample size calculations are an essential part of study design Consider
More informationAccelerated Failure Time Models
Accelerated Failure Time Models Patrick Breheny October 12 Patrick Breheny University of Iowa Survival Data Analysis (BIOS 7210) 1 / 29 The AFT model framework Last time, we introduced the Weibull distribution
More informationMonitoring Paired Binary Surgical Outcomes Using Cumulative Sum Charts
Monitoring Paired Binary Surgical Outcomes Using Cumulative Sum Charts Stefan H. Steiner and Richard J. Cook Department of Statistics and Actuarial Sciences University of Waterloo Waterloo, Ontario Canada
More informationAre Flexible Designs Sound?
Biometrics 62, 664 683 September 2006 Are Flexible Designs Sound? Carl-Fredrik Burman and Christian Sonesson AstraZeneca R & D, SE-431 83 Mölndal, Sweden email: carl-fredrik.burman@astrazeneca.com Summary.
More informationDesigning multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection
Research Article Statistics Received XXXX (www.interscience.wiley.com) DOI: 10.1002/sim.0000 Designing multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection Thomas
More informationSession 3 The proportional odds model and the Mann-Whitney test
Session 3 The proportional odds model and the Mann-Whitney test 3.1 A unified approach to inference 3.2 Analysis via dichotomisation 3.3 Proportional odds 3.4 Relationship with the Mann-Whitney test Session
More informationWhen enough is enough: early stopping of biometrics error rate testing
When enough is enough: early stopping of biometrics error rate testing Michael E. Schuckers Department of Mathematics, Computer Science and Statistics St. Lawrence University and Center for Identification
More informationSequential Analysis of Quality of Life Measurements Using Mixed Rasch Models
1 Sequential Analysis of Quality of Life Measurements Using Mixed Rasch Models Véronique Sébille 1, Jean-Benoit Hardouin 1 and Mounir Mesbah 2 1. Laboratoire de Biostatistique, Faculté de Pharmacie, Université
More information6-1. Canonical Correlation Analysis
6-1. Canonical Correlation Analysis Canonical Correlatin analysis focuses on the correlation between a linear combination of the variable in one set and a linear combination of the variables in another
More informationLecture 7. Proportional Hazards Model - Handling Ties and Survival Estimation Statistics Survival Analysis. Presented February 4, 2016
Proportional Hazards Model - Handling Ties and Survival Estimation Statistics 255 - Survival Analysis Presented February 4, 2016 likelihood - Discrete Dan Gillen Department of Statistics University of
More informationSemiparametric Regression
Semiparametric Regression Patrick Breheny October 22 Patrick Breheny Survival Data Analysis (BIOS 7210) 1/23 Introduction Over the past few weeks, we ve introduced a variety of regression models under
More informationPubH 7405: REGRESSION ANALYSIS INTRODUCTION TO LOGISTIC REGRESSION
PubH 745: REGRESSION ANALYSIS INTRODUCTION TO LOGISTIC REGRESSION Let Y be the Dependent Variable Y taking on values and, and: π Pr(Y) Y is said to have the Bernouilli distribution (Binomial with n ).
More informationHigh-Throughput Sequencing Course
High-Throughput Sequencing Course DESeq Model for RNA-Seq Biostatistics and Bioinformatics Summer 2017 Outline Review: Standard linear regression model (e.g., to model gene expression as function of an
More informationCourse Introduction and Overview Descriptive Statistics Conceptualizations of Variance Review of the General Linear Model
Course Introduction and Overview Descriptive Statistics Conceptualizations of Variance Review of the General Linear Model EPSY 905: Multivariate Analysis Lecture 1 20 January 2016 EPSY 905: Lecture 1 -
More informationTruncated Life Test Sampling Plan Under Odd-Weibull Distribution
International Journal of Mathematics Trends and Technology ( IJMTT ) Volume 9 Number 2 - July Truncated Life Test Sampling Plan Under Odd-Weibull Distribution G.Laxshmimageshpraba 1, Dr.S.Muthulakshmi
More informationWhether to use MMRM as primary estimand.
Whether to use MMRM as primary estimand. James Roger London School of Hygiene & Tropical Medicine, London. PSI/EFSPI European Statistical Meeting on Estimands. Stevenage, UK: 28 September 2015. 1 / 38
More information